Matthew R. Ritter
Corporate Officer/Principal bei EQUILLIUM, INC.
Profil
Matthew R.
Ritter is currently working as the Senior Vice President-Corporate Development at Equillium, Inc. He previously worked as a Principal at Lonza, Inc. and as a Manager-Research & Development at EyeCyte, Inc. Dr. Ritter completed his undergraduate degree at the University of California, Irvine and obtained a doctorate degree from the Keck School of Medicine of USC.
Aktive Positionen von Matthew R. Ritter
| Unternehmen | Position | Beginn |
|---|---|---|
| EQUILLIUM, INC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Matthew R. Ritter
| Unternehmen | Position | Ende |
|---|---|---|
Lonza, Inc.
 Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Corporate Officer/Principal | - |
EyeCyte, Inc.
 EyeCyte, Inc. Pharmaceuticals: MajorHealth Technology EyeCyte, Inc. develops products for the treatment of retinal disease. It focuses on treatments for age-related macular degeneration (AMD) and diabetic retinopathy. The company was founded by Mohammad El-Kalay and Martin Friedlander in 2008 and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Matthew R. Ritter
| University of California, Irvine | Undergraduate Degree |
| Keck School of Medicine of USC | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EQUILLIUM, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Lonza, Inc.
Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Process Industries |
EyeCyte, Inc.
EyeCyte, Inc. Pharmaceuticals: MajorHealth Technology EyeCyte, Inc. develops products for the treatment of retinal disease. It focuses on treatments for age-related macular degeneration (AMD) and diabetic retinopathy. The company was founded by Mohammad El-Kalay and Martin Friedlander in 2008 and is headquartered in La Jolla, CA. | Health Technology |
